Intalight's Advanced DREAM OCT Swept Source Imaging Technology Receives CE Mark
The CE Mark is the European Union (EU) approval for commercialization of DREAM OCT, the latest version of OCT. DREAM stands for: Deep, Rapid, Extensive, Accurate, and Multimodal. The imaging platform provides the highest quality OCT images currently available on the market.
"Intalight is extremely proud to have received CE Mark approval for DREAM OCT in Europe," said Shawn Peng, Chairman and Founder of Intalight. "This achievement enables us to provide European ophthalmologists with the most advanced technology, resulting in better outcomes for their patients."
DREAM OCT is able to cover an ultra-wide field of view in a single scan, providing 130° OCTA images. DREAM OCT™ Scan Source 12 mm Ultra-Deep Scanning provides superior imaging of the choroid and retina, as well as most of the vitreous space. Ultra-Deep Anterior Scanning capability reaches 16.2 mm (in air), scanning the entire anterior segment from the cornea to the anterior vitreous in a single scan. Longer wavelengths provide better penetration of opacities in the lens or vitreous.
"Over the past few years, we have heard from eye care professionals that they need a solution that allows them to image quickly, accurately, and deeply," said Bing Li, CEO and co-founder of Intalight. "DREAM OCT offers a full suite of imaging modalities for the most challenging retinal clinical and research applications, outperforming everything else HCPs know."
Using ultra-wide scan source technology, DREAM OCT is designed to meet the needs of retinal specialists, general ophthalmologists, and their patients, providing highly detailed imaging capabilities to improve care and treatment outcomes. More than 160 peer-reviewed papers have used research findings from DREAM OCT devices.
Joe Garibaldi, Chief Commercial Officer of Intalight, said: "This is exciting news for Intalight, with no longer a wait in Europe, we look forward to being able to offer this innovative solution in the U.S. We look forward to continuing to expand our prestigious network of institutions and ophthalmologists around the world with the recently received CE mark and final FDA clearance."
As the leader in clinically proven ultra-wide field of view OCTA, Intalight is currently working with top academic retina institutions and private retina clinics in the U.S., Europe and Asia.